TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed infantile, congenital, or pediatric fibrosarcoma~  * Initial biopsy or surgery performed within the past 35 days~* No evidence of distant metastases~* Available tissue for central review~PATIENT CHARACTERISTICS:~Age~* Under 2 at diagnosis~Performance status~* Zubrod Score (ECOG)~Life expectancy~* At least 8 weeks~Hematopoietic~* Absolute neutrophil count at least 1,000/mm\^3~* Platelet count at least 100,000/mm\^3\*~* Hemoglobin at least 10.0 g/dL\* NOTE: \*Transfusions allowed~Hepatic~* Total bilirubin no greater than 1.5 times upper limit of normal (ULN) (patients over 4 weeks of age)~  * Patients under 4 weeks of age with an indirect hyperbilirubinemia are eligible, provided the following criteria are met:~    * At least 2 bilirubin values at separate timepoints show a decrease in measurement~   * Direct bilirubin is no greater than 20% of the total bilirubin~* Direct bilirubin no greater than 1.5 times ULN~* Alanine Aminotransferase (ALT) less than 2.5 times ULN~Renal~* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min~PRIOR/CONCURRENT THERAPY:~Biologic therapy~* No concurrent sargramostim (GM-CSF)~Chemotherapy~* No prior chemotherapy~* No other concurrent anticancer chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior or concurrent radiotherapy except emergent radiotherapy for impending tracheal compression~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy plus possible surgery (Type: EXPERIMENTAL): Comprised of patients with disease lesions that are initially unresectable, or resected but with resulting grossly positive margins. All patients receive vincristine sulfate, dactinomycin, and cyclophosphamide (VAC), and mercaptoethane sulfonate (MESNA). Depending on response, patients may receive ifosfamide and etoposide (IE). Filgrastim may also be given, as needed. In addition to Chemotherapy, patients may receive Conventional Surgery.~(See Interventions section for drug dosage and administration details.)
- Surgery only (Type: EXPERIMENTAL): Comprised of patients with initially resectable disease lesions. All patients undergo Conventional Surgery. Those with a result of clear or microscopically positive margins remain on study in this arm, for observation with no further intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition criteria Diagnosis of Major Depressive Disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, social anxiety disorder or obsessive-compulsive disorder~* Must be able to receive a sertraline dose of 150 mg/day by the second screening visit (Day -15)~Exclusion Criteria~* Sexually active males or females, who could become pregnant, not agreeing to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days at the end of the study~* Diagnosed hypertension (including treated or untreated hypertension), or orthostatic hypotension~* Epilepsy or a history of seizures~* History of neuroleptic malignant syndrome or serotonin syndrome.~* Primary DSM-5 diagnosis of Schizophrenia spectrum and other psychotic disorders, Bipolar and related disorders, Feeding and eating disorders (including anorexia nervosa or bulimia), Neurocognitive disorders (including but not limited to delirium, major or mild neurocognitive disorder due to Alzheimer's, Parkinson's, or traumatic brain injury)~* A significant risk of committing violent acts, serious self-harm, or suicide~* History of diabetes mellitus (type 1 or type 2)~* Subjects with any previous exposure to brexpiprazole, or subjects with chronic use of prazosin or propranolol in the 90 days prior to the screening visit or any use in the 21 days (3 weeks) prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sertraline alone at steady state (Type: ACTIVE_COMPARATOR): To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
- Sertraline + brexpiprazole at steady state (Type: ACTIVE_COMPARATOR): To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Accuracy of Non-invasive Continuous CO2-Monitoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years with clinical indication of repeated arterial blood gas analyses~Exclusion Criteria:~* No informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed or suspected diagnosis of UCD~* Signed informed consent/Health Insurance Portability and Accountability Act (HIPAA) Authorization and medical records release~Exclusion Criteria:~* Any other reason that, in the Investigator's opinion, makes the patient unsuitable to participate in this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Topical 0.01% Atropine for the Control of Fast Progressing Myopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Children from 4 to 12 years~* Myopia from -1 to -6~* Fast progressing myopia (\>0.75 diopter / year)~* Informed consent obtained~Exclusion Criteria:~Astigmatism \> 1.5 diopters~* Anisometropia \> 2 diopters~* Concomitant pathology of anterior or posterior segments~* Other ocular diseases (Ocular inflammation, strabismus ...)~* Atropine hypersensitivity or allergy

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Atropine 0.01% (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient proved with infection of H. pylori in gastric mucosa~* Patient with signed informed consent.~Exclusion Criteria:~* woman in breast feeding or pregnancy.~* allergy or severe adverse effects to drugs used in study.~* severe complications of peptic ulcer disease (like perforation or obstruction).~* patients with history of cancer or failure of major organs.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Levofloxacin-Amoxicillin/clavulanate (Type: EXPERIMENTAL): 7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.
- Clarithromycin-Amoxicillin (Type: ACTIVE_COMPARATOR): 7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone Treatment for Prolonged Grief Disorder (PGD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older.~2. Lives within a reasonable distance from NYPH for convenient clinic visits.~3. Can speak, read, and write English proficiently.~4. Meet diagnostic criteria for PGD based on the DSM guidelines~5. If a female patient, must agree to use a method of contraception and be willing and able to continue contraception during the first 8 weeks of the study while she is taking the study drug. Female patients who are planning to use oral hormonal contraception during this time must have initiated it at least 2 months prior to the baseline visit.~6. If a male patient, must agree to use a method of contraception and be willing and able to continue contraception during the first 8 weeks of the study while he is taking the study drug.~Exclusion Criteria:~1. Having recently started taking/prescribed medications for any psychiatric illness (e.g. SSRIs for MDD) within the past 3 months; participants who have been taking this medication for longer than 3 months can be included.~2. Having recently started psychotherapy for any psychiatric illness within the past 3 months; participants who have been receiving psychotherapy for longer than 3 months can be included.~3. Prior history of recently active (e.g. within the past 3 months) opioid dependence.~4. Current prescription, non-prescription, or illicit opioid use, (i.e., acute use within the past 14 days or chronic use within the last 30 days), including opioid antagonists for alcohol or opioid dependence, all opioid analgesics, certain cough and cold remedies (e.g., codeine), and certain anti-diarrheal preparations (e.g., loperamide).~5. Possible future use of opioids during the study (e.g. for surgery).~6. Current use of leflunomide (Arava), droperidol (Droleptan), diazepam (Valium), thioridazine (Mellaril, Novoridazine, Thioril), or any other clinically relevant medication that has potential to cause liver injury with concurrent use of naltrexone.~7. Currently pregnant, lactating, or planning to become pregnant during the study.~8. Active hepatitis or liver disease.~9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels more than one standard deviation (SD) above the upper limit of normal on initial laboratory examination.~10. Screen positive for active suicidal thoughts or behaviors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 24 randomized patients will take placebo daily for 8 weeks.
- Naltrexone (Type: ACTIVE_COMPARATOR): 24 randomized patients will take naltrexone daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Motivation in Recent Onset Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder.~* Onset of diagnosis within 5 years.~* 14-30 years old.~* Clinically stable (outpatient status for 1 month and stable dose of medication for 1 month).~* Good general health~Exclusion Criteria:~* Substance dependence within the past 12 months,~* Current substance abuse,~* No history of neurological disorder

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- PRIME + CT (Type: EXPERIMENTAL): 4 months use of PRIME mobile application on mobile device and 30 hours of cognitive training
- Daily Goals + CT (Type: EXPERIMENTAL): 4 months use of Daily Goals mobile application on mobile device and 30 hours of cognitive training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Lavare Cycle in Patients Receiving HeartWare Left Ventricular Assist Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years~2. Approved for or supported with HeartWare durable LVAD~3. Capable of giving informed consent~Exclusion Criteria:~1. For those undergoing new device implantation:~   1. Age \<18 years~  2. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 1 at the time of implantation~  3. Presence of intra-cardiac thrombus~  4. History of thromboembolic event within previous 3 months of enrollment~2. For those with prior LVAD implantation with on-going support:~   1. Support duration \<3 months~  2. History of prior LVAD pump exchange~  3. History of LVAD pump hemolysis or thrombosis as defined by INTERMACS criteria~  4. History of stroke or transient ischemic event within previous 3 months of enrollment~  5. History of post-LVAD severe right ventricular failure as defined by INTERMACS criteria within previous 3 months of enrollment~  6. History of pump-related infection treated within previous 3 months of enrollment or those on chronic antibiotics suppressive therapy for pump related infection~  7. History of post-LVAD intra-cardiac or arterial thrombus or thromboembolic event within previous 3 months of enrollment~  8. International Normalized Ratio (INR) \<2 within previous 30-days from the date of enrollment~  9. Aspirin dose \<325 mg/day~  10. Lactate Dehydrogenase (LDH) levels ≥ 3 times the upper normal limit in previous 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lavare Cycle On (Type: ACTIVE_COMPARATOR): For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room.
- Lavare Cycle Off (Type: ACTIVE_COMPARATOR): For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II or III multiple myeloma according to Durie and Salmon criteria, patients older than 75 years, previously untreated patients.~Exclusion Criteria:~* Prior history of another neoplasm (except basocellular cutaneous or cervical epithelioma)~* Primary or associated amyloïdosis~* World Health organisation performance index of at least 3~* Significant renal insufficiency with creatinine serum levels of 5.0 mg per deciliter or more~* Cardiac or hepatic dysfunction~* Cerebral circulatory insufficiency~* Absolute contraindication to corticosteroids~* Peripheral neuropathy clinically significant~* History of venous thrombosis during the last 6 months~* HIV or hepatitis B or C positivity~* Patients who had geography, social, or psychological conditions which might prevent adequate follow-up.

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): 12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
- B (Type: ACTIVE_COMPARATOR): 12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy of Percutaneous Implantation of Autologous Myoblasts in Patients With Old Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of myocardial infarction, absence of viability.~* Ejection fraction under 40% or 45% in symptomatic patients~* Aged from 30-80 years old.~* Negative pregnancy test (women of childbearing age)~* Informed consent granted~Exclusion Criteria:~* Prior history of tachycardia or ventricular fibrillation (except in the acute phase of MI).~* Myocardial infarction with more than 10 years of evolution.~* Patients positive for HIV, HBV or HCB.~* Patients with organ dysfunction: liver and kidney function~* History of cancer or prior treatment with chemotherapy.~* The patient should not suffer from any concomitant severe and/or uncontrolled medical condition.~* Patients who, due to their geographical, psychiatric or social status, have difficulties in meeting the conditions established in the protocol.~* Pregnant or beast feeding women.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Skeletal myoblasts (Type: EXPERIMENTAL): Percutaneous autologous myoblast implantation
- No cells (Type: PLACEBO_COMPARATOR): Percutaneous culture medium without cells implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Disease Management in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women~2. 40 years or older~3. Having unstable COPD or Asthma~Exclusion Criteria:~1. Significant LV dysfunction~2. Other severe chronic morbidity compromising short-term survival~3. Significant cognitive impairment or psychiatric disease~4. Bedridden~5. Homeless or no telephone connection

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Disease Management (Type: EXPERIMENTAL): Comprehensive care delivered by designated nurses and pulmonologists, in collaboration with the primary practitioners and other healthcare professionals in the community
- Unual care (Type: ACTIVE_COMPARATOR): Care delivered by the primary practitioner with the advice of a consultant pulmonologist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy